Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry

Paul L. Hess; Kensey L. Gosch; Sandeep M. Jani; Paul D. Varosy; Steven M. Bradley; Thomas M. Maddox; P. Michael Ho; Salim S. Virani

doi:10.1016/j.ahj.2021.04.017

Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry

Paul L. Hess
, Kensey L. Gosch
, Sandeep M. Jani
, Paul D. Varosy
, Steven M. Bradley
, Thomas M. Maddox
, P. Michael Ho
, Salim S. Virani

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.

Original language	English
Pages (from-to)	58-62
Number of pages	5
Journal	American Heart Journal
Volume	240
DOIs	https://doi.org/10.1016/j.ahj.2021.04.017
State	Published - Oct 2021
Externally published	Yes

Access to Document

10.1016/j.ahj.2021.04.017

Cite this

@article{fc071c9cb4b443caad71d74b8f297f16,

title = "Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry",

abstract = "Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.",

author = "Hess, \{Paul L.\} and Gosch, \{Kensey L.\} and Jani, \{Sandeep M.\} and Varosy, \{Paul D.\} and Bradley, \{Steven M.\} and Maddox, \{Thomas M.\} and \{Michael Ho\}, P. and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = oct,

doi = "10.1016/j.ahj.2021.04.017",

language = "English",

volume = "240",

pages = "58--62",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Use of oral anticoagulants in patients with valvular atrial fibrillation

T2 - findings from the NCDR PINNACLE Registry

AU - Hess, Paul L.

AU - Gosch, Kensey L.

AU - Jani, Sandeep M.

AU - Varosy, Paul D.

AU - Bradley, Steven M.

AU - Maddox, Thomas M.

AU - Michael Ho, P.

AU - Virani, Salim S.

PY - 2021/10

Y1 - 2021/10

N2 - Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.

AB - Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.

UR - https://www.scopus.com/pages/publications/85109497162

U2 - 10.1016/j.ahj.2021.04.017

DO - 10.1016/j.ahj.2021.04.017

M3 - Letter

C2 - 34033802

AN - SCOPUS:85109497162

SN - 0002-8703

VL - 240

SP - 58

EP - 62

JO - American Heart Journal

JF - American Heart Journal

ER -

Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry

Abstract

Access to Document

Fingerprint

Cite this